SF 2645 In Committee
Formulary Committee members with a potential conflict of interest participation in committee communications and discussions authorization provision, public comment process for recommendations to the Formulary Committee development by the commissioner of human services requirement provision, and Minnesota Rare Disease Advisory Council expertise sought by the Formulary Committee requirement provision
Introduced
In Committee
Floor
Crossed Over
Passed
Enacted
No summary has been published for this bill. The full text is on the Bill text tab.
- Chamber
- Senate
- Introduced
- Mar 17, 2025
- Last action
- Mar 17, 2025 — Referred to Health and Human Services
- Session
- 2025-2026
- Momentum
- 31 · Low